CDD-2807

CDD-2807
Identifiers
	IUPAC name (3-([1,1'-Biphenyl]-2-ylethynyl)-1H-indazol-5-yl)(2,6-diazaspiro[3.5]nonan-2-yl)methanone;
Chemical and physical data
Formula	C29H26N4O
Molar mass	446.554 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(N1CC2(C1)CNCCC2)c1cc2c([NH]nc2C#Cc2ccccc2c2ccccc2)cc1;
	InChI InChI=InChI=1S/C29H26N4O/c34-28(33-19-29(20-33)15-6-16-30-18-29)23-12-14-27-25(17-23)26(31-32-27)13-11-22-9-4-5-10-24(22)21-7-2-1-3-8-21/h1-5,7-10,12,14,17,30H,6,15-16,18-20H2,(H,31,32); Key:YXMAOKMVGOSRPS-UHFFFAOYSA-N;

CDD-2807 is a chemical compound which acts as a potent and selective inhibitor of serine/threonine-protein kinase 33 (STK33), with a IC₅₀ of 9.2 nM. In animal studies it causes production of abnormal sperm with reduced motility, and it has been investigated as a potential male contraceptive drug.^[1]^[2]

References[edit]

^ Holdaway J, Georg GI (May 2024). "An emerging target for male contraception". Science. 384 (6698): 849–850. doi:10.1126/science.adp6432. PMID 38781397.
^ Ku AF, Sharma KL, Ta HM, Sutton CM, Bohren KM, Wang Y, et al. (May 2024). "Reversible male contraception by targeted inhibition of serine/threonine kinase 33". Science. 384 (6698): 885–890. doi:10.1126/science.adl2688. PMID 38781365.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[1] Holdaway J, Georg GI (May 2024). "An emerging target for male contraception". Science. 384 (6698): 849–850. doi:10.1126/science.adp6432. PMID 38781397.

[2] Ku AF, Sharma KL, Ta HM, Sutton CM, Bohren KM, Wang Y, et al. (May 2024). "Reversible male contraception by targeted inhibition of serine/threonine kinase 33". Science. 384 (6698): 885–890. doi:10.1126/science.adl2688. PMID 38781365.

[1]

[2]

See also[edit]

References[edit]